{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04448106",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CTX0020-002"
      },
      "Organization": {
        "OrgFullName": "Celltex Therapeutics Corporation",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis",
      "OfficialTitle": "Clinical Study for Subjects With Osteoarthritis of Knees, Hips, and Shoulders Using a Combination of Intravenous Infusions With Intra-articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)",
      "Acronym": "AdMSCs"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2021",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "August 1, 2021",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "August 1, 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "August 15, 2024",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "June 22, 2020",
      "StudyFirstSubmitQCDate": "June 23, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 25, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "July 7, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 8, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Celltex Therapeutics Corporation",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a phase 2 open-label, 6 arms (1 study group and 1 control group for each joint category), randomized control group clinical study with 300 subjects diagnosed with osteoarthritis of knees (n=100), hips (n=100) and shoulders (n=100). The study subjects will be evaluated for disease-associated severity according to symptoms, such as pain, mobility, daily active life, and functions using arthritis society established specific measurement tools related to the joints (KOOS and KSS for OA-knees: HOOS and HHS for OA-hips and ASES and CSS for OA-shoulders)."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Osteoarthritis, Knee",
          "Osteoarthritis, Hip",
          "Osteoarthritis Shoulder"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Autologous Adipose-derived Stem Cells (AdMSCs)"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "The Phase 2 study is an open-label, 6 arms, randomized, control group clinical study conducted in multiple clinical facilities.",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignMaskingDescription": "Patients and evaluators",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "300",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Phase 2 Arm 1 - OA Knee",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Celltex- AdMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 2 Arm 2 OA Knee",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Celltex- AdMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 2 Arm 3 - OA Hip",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Celltex- AdMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 2 Arm 4 - OA Hip",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Celltex- AdMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 2 Arm 5 - OA Shoulder",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Celltex- AdMSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 2 Arm 6 - OA Shoulder",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Celltex- AdMSCs"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Celltex- AdMSCs",
            "InterventionDescription": "Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase 2 Arm 1 - OA Knee",
                "Phase 2 Arm 2 OA Knee",
                "Phase 2 Arm 3 - OA Hip",
                "Phase 2 Arm 4 - OA Hip",
                "Phase 2 Arm 5 - OA Shoulder",
                "Phase 2 Arm 6 - OA Shoulder"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "AdMSCs"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "the frequency and nature of adverse events occurring during the study based on the annualized rate of all AdMSC-associated adverse events (AEs) in all subjects.",
            "PrimaryOutcomeDescription": "safety",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "Any organ damage or safety concerns determined by SMAC 20 blood test.",
            "PrimaryOutcomeDescription": "Safety",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change of Knee injury and Osteoarthritis Outcome Score (KOOS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients",
            "SecondaryOutcomeDescription": "efficacy",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change of Knee Society Score (KSS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients",
            "SecondaryOutcomeDescription": "efficacy",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change of Hip disability and Osteoarthritis Outcome Score (HOOS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients",
            "SecondaryOutcomeDescription": "efficacy",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change of Harris Hip Score (HHS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients",
            "SecondaryOutcomeDescription": "efficacy",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Change of the American Shoulder and Elbow Surgeons Shoulder Score (ASES, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients",
            "SecondaryOutcomeDescription": "efficacy",
            "SecondaryOutcomeTimeFrame": "12 month"
          },
          {
            "SecondaryOutcomeMeasure": "Change of Constant shoulder score (CSS, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients",
            "SecondaryOutcomeDescription": "efficacy",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "changes in joint images (X-ray or MRI) from the baseline",
            "SecondaryOutcomeDescription": "efficacy",
            "SecondaryOutcomeTimeFrame": "12 months"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Number of patients achieve visual analog scale (VAS) pain improvement above 30%, 50% and 70% from the baseline",
            "OtherOutcomeDescription": "efficacy",
            "OtherOutcomeTimeFrame": "12 months"
          },
          {
            "OtherOutcomeMeasure": "Number of patient achieve Image (X-ray or MRI) improvement above 30%, 50% and 70% from the baseline",
            "OtherOutcomeDescription": "efficacy",
            "OtherOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge above 18 years\nMale or female\nSubjects in study group must have banked AdMSCs at Celltex (already passed communicable disease screen tests for HIV, syphilis and Hepatitis B and C during banking stage)\nMust understand and voluntarily sign an Informed Consent for study participation obtained prior to undergoing any study-specific procedures\nMust be diagnosed as OA-knees, OA-hips, or OA-shoulders by radiographic criteria and physical examination.\n\nExclusion Criteria:\n\nParticipation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start\nUnwillingness or inability to comply with study procedures\nPatients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc.\nClinically active malignant disease\nPrevious thrombotic disorder\nHistory of known pulmonary embolism or known secondary anti-phospholipid syndrome\nKnown or suspected hypersensitivity to any components used to culture the AdMSCs, e.g. BSA and sulfur-containing products (e.g., DMSO)\nMajor trauma or surgery within 14 days of study treatment start\nMental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study\nAlcohol, drug, or medication abuse within one year prior to study treatment start\nAny condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study\nIrreversible severe end-organ failure, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions\nPatients or family history with a hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc.\nHistory of long-term use of immunosuppressive agents\nOrgan transplants in the previous 6 months\nPregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Sally McGahee",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "7135546847",
            "CentralContactEMail": "smcgahee@celltexbank.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Derek W Guillory, MD.",
            "OverallOfficialAffiliation": "Root Causes Medicine",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010003",
            "ConditionMeshTerm": "Osteoarthritis"
          },
          {
            "ConditionMeshId": "D000020370",
            "ConditionMeshTerm": "Osteoarthritis, Knee"
          },
          {
            "ConditionMeshId": "D000015207",
            "ConditionMeshTerm": "Osteoarthritis, Hip"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000001168",
            "ConditionAncestorTerm": "Arthritis"
          },
          {
            "ConditionAncestorId": "D000007592",
            "ConditionAncestorTerm": "Joint Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          },
          {
            "ConditionAncestorId": "D000012216",
            "ConditionAncestorTerm": "Rheumatic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M12078",
            "ConditionBrowseLeafName": "Osteoarthritis",
            "ConditionBrowseLeafAsFound": "Osteoarthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21321",
            "ConditionBrowseLeafName": "Osteoarthritis, Knee",
            "ConditionBrowseLeafAsFound": "Osteoarthritis, Knee",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M17064",
            "ConditionBrowseLeafName": "Osteoarthritis, Hip",
            "ConditionBrowseLeafAsFound": "Osteoarthritis, Hip",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3628",
            "ConditionBrowseLeafName": "Arthritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9773",
            "ConditionBrowseLeafName": "Joint Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14197",
            "ConditionBrowseLeafName": "Rheumatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5475",
            "ConditionBrowseLeafName": "Collagen Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          }
        ]
      }
    }
  }
}